June 16, 2021 -- California-based Dendreon Pharmaceuticals announced that it will offer end-to-end manufacturing for complex cell therapies.
The company is one of only four firms that manufacture cell therapies for commercial use in the U.S. In early 2021, Dendreon started to dedicate capacity for later-stage partner programs within its current infrastructure.